Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.32 |
| ▸ | TOP2A | P11388 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 2/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | GLS | O94925 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30694034 | 1.00 | GLA (0.34) | GLAFKBP1ATOP2AFAAHCHRM2 | |
| SCHEMBL958204 | 0.84 | CHRM2 (0.35) | GLAFKBP1ATOP2AFAAHCHRM2 | |
| SCHEMBL625416 | 0.84 | CHRM2 (0.35) | GLAFKBP1ATOP2AFAAHCHRM2 | |
| SCHEMBL211419 | 0.84 | CHRM2 (0.35) | GLAFKBP1ATOP2AFAAHCHRM2 | |
| SCHEMBL28717400 | 0.81 | GLA (0.38) | GLAFKBP1ATOP2AFAAHCHRM2 | |
| SCHEMBL31080065 | 0.80 | GLA (0.38) | GLACHRM2CHRM1CHRM3DDB1 | |
| SCHEMBL31080875 | 0.80 | ALDH1A1 (0.37) | FKBP1ATOP2AFAAHALDH1A1USP2 | |
| SCHEMBL7123624 | 0.80 | ALDH1A1 (0.37) | FKBP1ATOP2AFAAHALDH1A1USP2 | |
| SCHEMBL31501958 | 0.79 | FKBP1A (0.38) | GLAFKBP1ATOP2AFAAHCHRM2 | |
| SCHEMBL31501836 | 0.79 | TOP2A (0.36) | GLAFKBP1ATOP2AFAAHGLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963319-B1 | HETEROARYLPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-04-11 | — | — | EP | disclosed |
| US-7618982-B2 | Heteroarylpyrrolopyridinones active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-11-17 | — | — | US | disclosed |
| US-20070142415-A1 | Heteroarylpyrrolopyridinones active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142415-A1 | Heteroarylpyrrolopyridinones active as kinase inhibitors | MAP3K1, MAP3K19, MAP3K3 | GLA 3328/4885FKBP1A 4096/4885TOP2A 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.